Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Underwood

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
The American Journal of Psychiatry|March 3, 2004
Absence of histological lesions in primate models of ECT and magnetic seizure therapyAndrew J Dwork, Victoria Arango, Mark Underwood, et al.
Current Urology|June 12, 2014
A prospective study of the role of inflammation in bladder cancerTahir Qayyum, Peter McArdle, Mustafa Hilmy, et al.
The Journal of Antimicrobial Chemotherapy|June 27, 2013
In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravirFilippo Canducci, Elisa Rita Ceresola, Diego Saita, et al.
The Prostate|August 27, 2020
Inflammatory infiltration is associated with AR expression and poor prognosis in hormone naïve prostate cancerMilly McAllister, Vera Constâncio, Samantha Patek, et al.
Viruses|March 28, 2024
Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 StudiesMark Underwood, Rimgaile Urbaityte, Ruolan Wang, et al.
Antimicrobial Agents and Chemotherapy|October 25, 2021
Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING StudyMark Underwood, Joe Horton, Keith Nangle, et al.
Antimicrobial Agents and Chemotherapy|February 16, 2023
Correction for Underwood et al., "Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study"Mark Underwood, Joe Horton, Keith Nangle, et al.
Open Forum Infectious Diseases|March 26, 2025
Efficacy and Safety Outcomes in Adults Initiating Dolutegravir/Lamivudine With High Viral Load in the GEMINI-1/-2 and STAT TrialsCharlotte-Paige Rolle, José R Arribas, Roberto Ortiz, et al.
Antimicrobial Agents and Chemotherapy|January 9, 2013
Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572)Cindy Vavro, Samiul Hasan, Heather Madsen, et al.
The Australian and New Zealand Journal of Psychiatry|November 23, 2020
Informing National Health Service patients about participation in clinical research: A comparison of opt-in and opt-out approaches across the United KingdomCatherine Henshall, Jennifer Potts, Sophie Walker, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
The American Journal of Psychiatry|March 3, 2004
Absence of histological lesions in primate models of ECT and magnetic seizure therapyAndrew J Dwork, Victoria Arango, Mark Underwood, et al.
Current Urology|June 12, 2014
A prospective study of the role of inflammation in bladder cancerTahir Qayyum, Peter McArdle, Mustafa Hilmy, et al.
The Journal of Antimicrobial Chemotherapy|June 27, 2013
In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravirFilippo Canducci, Elisa Rita Ceresola, Diego Saita, et al.
The Prostate|August 27, 2020
Inflammatory infiltration is associated with AR expression and poor prognosis in hormone naïve prostate cancerMilly McAllister, Vera Constâncio, Samantha Patek, et al.
Viruses|March 28, 2024
Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 StudiesMark Underwood, Rimgaile Urbaityte, Ruolan Wang, et al.
Antimicrobial Agents and Chemotherapy|October 25, 2021
Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING StudyMark Underwood, Joe Horton, Keith Nangle, et al.
Antimicrobial Agents and Chemotherapy|February 16, 2023
Correction for Underwood et al., "Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study"Mark Underwood, Joe Horton, Keith Nangle, et al.
Open Forum Infectious Diseases|March 26, 2025
Efficacy and Safety Outcomes in Adults Initiating Dolutegravir/Lamivudine With High Viral Load in the GEMINI-1/-2 and STAT TrialsCharlotte-Paige Rolle, José R Arribas, Roberto Ortiz, et al.
Antimicrobial Agents and Chemotherapy|January 9, 2013
Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572)Cindy Vavro, Samiul Hasan, Heather Madsen, et al.
The Australian and New Zealand Journal of Psychiatry|November 23, 2020
Informing National Health Service patients about participation in clinical research: A comparison of opt-in and opt-out approaches across the United KingdomCatherine Henshall, Jennifer Potts, Sophie Walker, et al.
Pageof 6